- Home
- ALXO vs BYSI Comparison
ALXO vs BYSI Comparison
Compare ALXO & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- BYSI
- Stock Information
- Founded
- ALXO 2015
- BYSI 2010
- Country
- ALXO United States
- BYSI United States
- Employees
- ALXO N/A
- BYSI N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- BYSI Health Care
- Exchange
- ALXO Nasdaq
- BYSI Nasdaq
- Market Cap
- ALXO 76.5M
- BYSI 72.1M
- IPO Year
- ALXO 2020
- BYSI 2017
- Fundamental
- Price
- ALXO $1.12
- BYSI $1.79
- Analyst Decision
- ALXO Buy
- BYSI
- Analyst Count
- ALXO 6
- BYSI 0
- Target Price
- ALXO $6.64
- BYSI N/A
- AVG Volume (30 Days)
- ALXO 769.2K
- BYSI 10.8K
- Earning Date
- ALXO 03-06-2025
- BYSI 01-01-0001
- Dividend Yield
- ALXO N/A
- BYSI N/A
- EPS Growth
- ALXO N/A
- BYSI N/A
- EPS
- ALXO N/A
- BYSI N/A
- Revenue
- ALXO N/A
- BYSI $1,876,000.00
- Revenue This Year
- ALXO N/A
- BYSI N/A
- Revenue Next Year
- ALXO N/A
- BYSI N/A
- P/E Ratio
- ALXO N/A
- BYSI N/A
- Revenue Growth
- ALXO N/A
- BYSI 21.03
- 52 Week Low
- ALXO $0.96
- BYSI $1.05
- 52 Week High
- ALXO $17.83
- BYSI $4.00
- Technical
- Relative Strength Index (RSI)
- ALXO 38.53
- BYSI 56.87
- Support Level
- ALXO $1.00
- BYSI $1.61
- Resistance Level
- ALXO $1.22
- BYSI $1.88
- Average True Range (ATR)
- ALXO 0.09
- BYSI 0.10
- MACD
- ALXO 0.00
- BYSI 0.00
- Stochastic Oscillator
- ALXO 35.12
- BYSI 66.67
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.